BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:OriCell Therapeutics Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies OriCell Therapeutics Co.\, Ltd.'s
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06182696-3263@assetmemo.bio
DTSTAMP:20261121T005937Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:OriCAR-017: Phase 1/2 readout est. (NCT06182696)
DESCRIPTION:OriCAR-017\, phase 1/2\, Multiple Myeloma.\nStudy: OriCAR-017 C
 himeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
 \nEstimated primary completion: 30 November 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/oricar-017#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06182696
URL:https://assetmemo.bio/drug/oricar-017#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
